Product Support & Resources

2022 Formulary update

Emgality remains Preferred Brand Tier on CVS National Commercial Template Formularies and Aimovig^® is no longer on the Preferred Brand Tier^a

^aFor the preventive treatment of migraine Emgality and Ajovy^® remain in the Preferred Brand Tier across CVS Caremark Value Formulary, Advanced Control Formulary, CVS Caremark Performance Drug List - Standard Control, and CVS Caremark Performance Drug List- Standard Opt Out Commercial Formularies. Aimovig^® is excluded, effective 1/1/2022, on all previously listed formularies except the CVS Caremark Performance Drug List- Standard Opt Out formulary.

Emgality has the best-in-class^b commercial access for the preventive treatment of migraine^2,3

^bBest-in-class commercial access indicates the subcutaneous calcitonin gene-related peptide (CGRP) antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial plans for the preventive treatment of migraine.² Does not take into consideration any restrictions set forth by individual plans. Data as of 11/2021.

As of 1/1/2022, Emgality is the ONLY injectable CGRP antagonist with⁴

Source: Managed Markets Insight & Technology (MMIT), LLC as of 01/2022 and is subject to change without notice. Please contact the plan or state for the most current information. “Coverage” includes all statuses at or equivalent to Preferred, Covered, Specialty, or Generic for the preventive treatment of migraine. This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Employers and employer groups may also offer additional benefit designs, which may be different than described.

Have questions about Emgality?

Call us at 1-833-EMGALITY (1-833-364-2548).

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

For your eligible, commercially insured patients with migraine or episodic cluster headache,

Get your patients started on Emgality: 1 savings card^a for 2 headache conditions¹

Patients can get Emgality for as little as $0 for up to 12 months

Help patients save with the Emgality Savings Card^a

Download savings card(s)

^aOffer good until 12/31/2022 for up to 12 months of Emgality. Patients that have commercial drug insurance but do not have coverage for Emgality may be able to pay as little as $0 for their first fill of Emgality. Patients that have commercial drug insurance and have coverage for Emgality may be able to pay as little as $0 per fill. Offer subject to a monthly cap and a separate annual cap. Monthly and annual caps are set at Lilly’s absolute discretion and may be changed by Lilly with or without notice. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or whose prescription claims for Emgality are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

PA=prior authorization.

TRICARE^® is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved.

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Request your Emgality Loading Dose Kit samples, delivered by your Lilly Sales Representative^a

The Loading Dose Kit (sample) lets you provide patients living with migraine a chance to try out administering the first monthly dose of Emgality (2 injections of 120 mg each), right in your office. After that, patients can inject 1 dose, or injection, on their own each month. Loading Dose Kits (samples) are intended to assess tolerability and efficacy for individual patients in the office.

To request your loading dose kit samples, use the link below to complete and submit your request electronically. Your Rep will deliver your samples directly to your office.

Sample/Sales Representative Request Form

^aSamples are not available for episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

These resources are available for your practice

Dosing and Prescribing Comparison by Indication